Cargando…

Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States

BACKGROUND: A range of treatments for patients with severe hemophilia A (HA) have been developed over the last decade, allowing for reduced frequency of administration and improved outcomes (joint health and breakthrough bleeding rates). While clinically effective, the cost effectiveness of these tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bullement, Ash, Knowles, Emma S., DasMahapatra, Pronabesh, Ali, Talaha, Preblick, Ron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611150/ https://www.ncbi.nlm.nih.gov/pubmed/34268704 http://dx.doi.org/10.1007/s41669-021-00283-6

Ejemplares similares

Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis
por: Preblick, Ronald, et al.
Publicado: (2020)

Bleeding management: rFVIIIFc in hemophilia A and liver transplantation
por: Grottke, Oliver, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
por: Bullement, Ash, et al.
Publicado: (2019)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
por: Traets, Marissa J.M., et al.
Publicado: (2020)

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials
por: Klamroth, Robert, et al.
Publicado: (2021)

Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
por: Chang, Chia-Yau, et al.
Publicado: (2023)

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study
por: Pasi, John, et al.
Publicado: (2022)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes
por: Giraud, Romain, et al.
Publicado: (2021)

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany
por: Olivieri, Martin, et al.
Publicado: (2020)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII
por: Swiech, Kamilla, et al.
Publicado: (2011)

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
por: Oldenburg, Johannes, et al.
Publicado: (2019)

Königs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022;139(26):3699-3707.
Publicado: (2023)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
por: Kenet, Gili, et al.
Publicado: (2023)

Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81–8973 compared with other full-length rFVIII products
por: Teare, John M, et al.
Publicado: (2019)

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS
por: Lalezari, S, et al.
Publicado: (2014)

Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection
por: Solms, Alexander, et al.
Publicado: (2020)

SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A
por: Tiede, Andreas, et al.
Publicado: (2019)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Patient-centered activity monitoring in the self-management of chronic health conditions
por: Chiauzzi, Emil, et al.
Publicado: (2015)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Mobility assessment using wearable technology in patients with late-onset Pompe disease
por: Hamed, Alaa, et al.
Publicado: (2019)

Clinical trials from the patient perspective: survey in an online patient community
por: DasMahapatra, Pronabesh, et al.
Publicado: (2017)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

Development of the Fabry Disease Patient-Reported Outcome (FD-PRO): a new instrument to measure the symptoms and impacts of Fabry Disease
por: Hamed, Alaa, et al.
Publicado: (2021)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Factors in Patient Empowerment: A Survey of an Online Patient Research Network
por: Chiauzzi, Emil, et al.
Publicado: (2016)

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
por: Kim, Ju Young, et al.
Publicado: (2019)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
por: Liu, Chao Lien, et al.
Publicado: (2016)

In search of a daily physical activity “sweet spot”: Piloting a digital tracking intervention for people with multiple sclerosis
por: Chiauzzi, Emil, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dma8dg2u8uckd46h53hrkpqngq